Robert Winn, MD, of the Virginia Commonwealth University Massey Cancer Center, discusses the creation of a health equity report card to track how institutions are dealing with disparities in oncology care, ways to recognize bias in care, and adding health equity experts to guideline panels and other advisory groups.
Thomas K. Varghese, Jr, MD, of Huntsman Cancer Institute at the University of Utah, summarizes a panel discussion on how the COVID-19 pandemic has interrupted cancer screenings, when telemedicine works and when it doesn’t, opening alternative care sites in the community, and the emotional and mental toll the coronavirus has taken on health-care providers.
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating patients with triple-negative breast cancer; data on early-stage and advanced disease; and the role of checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.
Alexander E. Perl, MD, of the Abramson Cancer Center at the University of Pennsylvania, discusses the major changes in 2021 to the NCCN Clinical Practice Guidelines in Oncology for managing acute myeloid leukemia, including venetoclax plus azacitidine, a new standard of care in patients ineligible for intensive induction; oral azacitidine maintenance in fit patients unable to complete intensive consolidation chemotherapy or proceed to transplant; and an increased focus on minimal residual disease status post-induction.
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the several hereditary renal cell cancer syndromes, the importance of surveillance for both renal and nonrenal manifestations, and the treatment options available.
Susan M. Swetter, MD, of Stanford Cancer Institute, discusses molecular prognostic tests for cutaneous melanoma, which may improve staging accuracy, reduce unnecessary sentinel lymph node biopsies, and inform decisions on surveillance imaging and/or adjuvant therapy.
